SIRT1 mediated inhibition of VEGF/VEGFR2 signaling by Resveratrol and its relevance to choroidal neovascularization

Cytokine

Volumn 76, Issue 2, 2015, Pages 549-552

  Zhang, Huiming ^a,b   He, Shikun ^b   Spee, Christine ^b   Ishikawa, Keijiro ^c   Hinton, David R ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c DOHENY EYE INSTITUTE   (United States)

Author keywords

CNV; HIF 1 ; Resveratrol; RPE; SIRT1; VEGFR2

Indexed keywords

COBALT CHLORIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RESVERATROL; SIRTUIN 1; SMALL INTERFERING RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; HIF1A PROTEIN, HUMAN; SIRT1 PROTEIN, HUMAN; STILBENE DERIVATIVE; VASCULOTROPIN A;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SUBRETINAL NEOVASCULARIZATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

CELL LINE; CHOROIDAL NEOVASCULARIZATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SIRTUIN 1; STILBENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84943816240     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.06.019     Document Type: Article

References (12)

1. Grossniklaus H.E., Green W.R. Choroidal neovascularization. Am. J. Ophthalmol. 2004, 137:496-503.
2. Strauss O. The retinal pigment epithelium in visual function. Physiol. Rev. 2005, 85:845-881.
3. Veritti D., Sarao V., Lanzetta P. Neovascular age-related macular degeneration. Ophthalmol. J. Int. D'ophtalmol.: Int. J. Ophthalmol., Z. Augenheilkunde 2012, 227(Suppl. 1):11-20.
4. Yang Z., Wang H., Jiang Y., Hartnett M.E. VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis. Am. J. Pathol. 2014, 184:1230-1239.
5. Bola C, Bartlett H, Eperjesi F. Resveratrol and the eye: activity and molecular mechanisms. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2014. doi:10.1007/s00417-014-2604-8.
6. Kulkarni S.S., Canto C. The molecular targets of Resveratrol. Biochim. Biophys. Acta 2014, 10.1016/j.bbadis.2014.10.005.
7. Balaiya S., Murthy R.K., Chalam K.V. Resveratrol inhibits proliferation of hypoxic choroidal vascular endothelial cells. Mol. Vision 2013, 19:2385-2392.
8. Nagineni C.N., Raju R., Nagineni K.K., Kommineni V.K., Cherukuri A., Kutty R.K., Hooks J.J., Detrick B. Resveratrol suppresses expression of VEGF by human retinal pigment epithelial cells: potential nutraceutical for age-related macular degeneration. Aging Dis. 2014, 5:88-100.
9. Nagai N., Kubota S., Tsubota K., Ozawa Y. Resveratrol prevents the development of choroidal neovascularization by modulating AMP-activated protein kinase in macrophages and other cell types. J. Nutr. Biochem. 2014, 10.1016/j.jnutbio.2014.05.015.
10. Kanavi M.R., Darjatmoko S., Wang S., Azari A.A., Farnoodian M., Kenealey J.D., van Ginkel P.R., Albert D.M., Sheibani N., Polans A.S. The sustained delivery of resveratrol or a defined grape powder inhibits new blood vessel formation in a mouse model of choroidal neovascularization. Molecules 2014, 19:17578-17603.
11. Witmer A.N., Vrensen G.F., Van Noorden C.J., Schlingemann R.O. Vascular endothelial growth factors and angiogenesis in eye disease. Progr. Retinal Eye Res. 2003, 22:1-29.
12. Chen L.K., Qiang P.F., Xu Q.P., Zhao Y.H., Dai F., Zhang L. Trans-3,4,5,4'-tetramethoxystilbene, a resveratrol analog, potently inhibits angiogenesis in vitro and in vivo. Acta Pharmacol. Sin. 2013, 34:1174-1182.